– WATCH
Learn more about Bexion Pharmaceuticals through our highlights video
– WATCH
Bexion Pharmaceuticals President & CEO Ray Takigiku featured on ADVANCEMENTS TV with Ted Danson
In this episode, Advancements will explore how lysosomes play a role in a broad range of diseases including cancer, Alzheimer’s, Parkinson’s, and even infectious diseases such as viruses and bacteria. Hearing from experts in the field, audiences will discover how Bexion Pharmaceuticals, Inc. (Bexion) – a clinical stage biotech company– is leveraging the lysosome’s role to treat even very advanced cancers and improve patient’s quality of life.
– WATCH
Dr. Richard Curry, III Medical Director at CTI and Medical Affairs Advisory at Bexion Pharmaceuticals, Inc. recently presented at the 3rd Annual Glioblastoma Drug Development Summit.
Bexion in Innovation Express
Innovation Express is a multi-media healthcare news hub designed to share all Innovation Healthcare Institute (IHCI) events and programs and announce the most innovative items in healthcare. Bexion Pharmaceuticals, Inc. was recently featured in Innovations Express. Please click on the link below to read the article and learn more about our organization.
– Our Platform
An innovative, targeted approach to treating cancer
For the last 20 years since the mapping of the human genome, many cancer therapeutics have targeted cellular mutations and not the cancer cells’ environment.
By utilizing a small lysosomal protein known as Saposin C our approach specifically targets unique features of cancer cells and their environment, including externalized phosphatidylserine and tumor cell lysosomes.
– Our Pipeline
A Pipeline-in-a-Product asset with potential for multiple indications
BXQ-350 is the foundation of our pipeline. Early clinical results have shown a strong safety and tolerability profile.
– clinical trials
Update
Our clinical trials are regulated by the Food and Drug Administration (FDA) in the United States and by similar regulatory agencies worldwide.
Resources
Resources
News
Bexion Pharmaceuticals, Inc. to Present at the 2022 International Symposium on Pediatric Neuro-Oncology (IPSNO) Annual Conference
FOR IMMEDIATE RELEASE [Covington, KY---June 13, 2022] Bexion Pharmaceuticals, Inc., a mid-stage clinical biopharmaceutical company, announced today that two abstracts submitted for an in-person session at the IPSNO annual meeting to be held in Hamburg, Germany, June 12-15, 2022 has been chosen for poster presentation. ISPNO is the largest international scientific meeting of multidisciplinary professionals ... Read More
Bexion Pharmaceuticals, Inc. Welcomes New Chief Financial Officer
Seasoned BIO/Pharma Executive adds finance, strategic capital access and public market readiness to the management team FOR IMMEDIATE RELEASE [Covington, KY---June 2, 2022l] Bexion Pharmaceuticals, Inc., a mid-stage biopharmaceutical company developing innovative therapies for cancers and chemotherapy induced peripheral neuropathy (CIPN), announced today that Ms. Joyce LaViscount has joined the Company’s leadership team as Chief ... Read More